Logo

Kuniko Nishikawa

May 02, 2017

Analytics firm Fronteo Healthcare has chosen Kuniko Nishikawa as its new CEO. Nishikawa had been an independent director of the healthcare subsidiary of Tokyo-based Fronteo Inc. since December. She replaces previous CEO Naritomo Ikeue, who has agreed to remain on the board of directors, overseeing business development for Fronteo Healthcare. The company also named Masahiro Morimoto executive chairman. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.